SCHEMBL3859855

SCHEMBL3859855

O=C(O)c1ccccc1NN=C(N=Nc1ccccc1)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.61
NPC1 O15118 6/20 0.61
L3MBTL1 Q9Y468 3/20 0.61
TP53 P04637 1/20 0.51
MDM2 Q00987 1/20 0.51
MEN1 O00255 6/20 0.50
KMT2A Q03164 6/20 0.50
ALDH1A1 P00352 4/20 0.50
MAPT P10636 4/20 0.50
GAA P10253 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MAPK1 P28482 1/20 0.48
RECQL P46063 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KDM4E B2RXH2 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
POLB P06746 1/20 0.45
PKM P14618 1/20 0.43
AGTR1 P30556 1/20 0.43
PTBP1 P26599 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4074991 1.00 RAB9A (0.61) RAB9ANPC1L3MBTL1TP53MDM2
SCHEMBL3859850 1.00 RAB9A (0.61) RAB9ANPC1L3MBTL1TP53MDM2
SCHEMBL7509714 1.00 RAB9A (0.61) RAB9ANPC1L3MBTL1TP53MDM2
SCHEMBL16139607 0.84 TP53 (0.61) RAB9ANPC1L3MBTL1TP53MDM2
SCHEMBL9130160 0.82 TP53 (0.46) RAB9ANPC1L3MBTL1TP53MDM2
SCHEMBL3064886 0.81 RAB9A (0.55) RAB9ANPC1L3MBTL1TP53MDM2
SCHEMBL3064889 0.81 RAB9A (0.55) RAB9ANPC1L3MBTL1TP53MDM2
SCHEMBL3077670 0.79 RAB9A (0.53) RAB9ANPC1L3MBTL1TP53MDM2
SCHEMBL3077671 0.79 RAB9A (0.53) RAB9ANPC1L3MBTL1TP53MDM2
SCHEMBL19752044 0.77 TP53 (0.57) RAB9ANPC1L3MBTL1TP53MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193168-B2 Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release REDPOINT BIO CORPORATION (US) 2012-06-05 US claimed
EP-2107908-A2 USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE Redpoint Bio Corporation (US) 2009-10-14 EP claimed
US-20080306030-A1 Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release REDPOINT BIO CORPORATION (US) 2008-12-11 US claimed
WO-2008097504-A2 USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE REDPOINT BIO CORPORATION (US) 2008-08-14 WO claimed
US-20070207093-A1 Hydrazone derivatives and uses thereof LINQUAGEN CORP. 2007-09-06 US claimed
US-8193168-B2 Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release REDPOINT BIO CORPORATION (US) 2012-06-05 US disclosed
EP-2107908-A2 USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE Redpoint Bio Corporation (US) 2009-10-14 EP disclosed
EP-1951215-A4 HYDRAZONE DERIVATIVES AND USES THEREOF REDPOINT BIO CORP (US) 2009-07-29 EP disclosed
US-20080306030-A1 Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release REDPOINT BIO CORPORATION (US) 2008-12-11 US disclosed
WO-2008097504-A2 USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE REDPOINT BIO CORPORATION (US) 2008-08-14 WO disclosed
EP-1951215-A2 HYDRAZONE DERIVATIVES AND USES THEREOF Redpoint Bio Corporation (US) 2008-08-06 EP disclosed
US-20070207093-A1 Hydrazone derivatives and uses thereof LINQUAGEN CORP. 2007-09-06 US disclosed
WO-2007056159-A2 HYDRAZONE DERIVATIVES AND USES THEREOF REDPOINT BIO CORPORATION (US) 2007-05-18 WO disclosed
US-20020106590-A1 AQUEOUS THERMALLY BEACHABLE COMPOSITION USEFUL IN A PHOTOTHERMOGRAPHIC ELEMENT CARESTREAM HEALTH, INC. 2002-08-08 US disclosed
EP-1217431-A2 An aqueous thermally bleachable composition useful in a photothermographic element EASTMAN KODAK COMPANY (US) 2002-06-26 EP disclosed
US-4201588-A NONSILVER PHOTOGRAPHIC FILMS; DISULFIDE, DIAZOANTHRONE, DIAZOPHENANTHRONE, AROMATIC AZIDE, CARBAZIDES OR QUINONES AS PHOTOREDUCTANT; EXTERNAL HYDROGEN SOURCE EASTMAN KODAK COMPANY (US) 1980-05-06 US disclosed
US-4201590-A Heat sensitive reactive products of hexaarylbiimidazole and antihalation dyes EASTMAN KODAK COMPANY (US) 1980-05-06 US disclosed
US-4196002-A HEXAARYLBISMIIDAZOLE, COLORLESS EASTMAN KODAK COMPANY (US) 1980-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207093-A1 Hydrazone derivatives and uses thereof TAS2R1, TAS2R5, TAS1R1 RAB9A 2563/4885NPC1 2078/4885L3MBTL1 3572/4885
US-20080306030-A1 Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release GLP1R, GIPR, TRPM5 RAB9A 1870/4885NPC1 922/4885L3MBTL1 3723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.